What GLP-1s Can't Decide For You

The Truth About Starting, Stopping, and What's Actually Yours to Control

“I started Ozempic, lost some real weight, but the nausea and the fatigue got so bad I had to stop. Now it's coming back and I feel like I failed at the one thing that was finally working.”

If that's you, or close to it, we want to say something clearly, before anything else: you didn't fail. You're describing exactly what the research says happens, almost on schedule.

We wrote about GLP-1 medications back in 2024, when the conversation was mostly “should I start?” A lot of our clients have moved past that question. You started. You may have stopped, because of the nausea, the cost, the fatigue, or simply because the prescription wasn't sustainable. Now you're standing in the after, wondering what that means for you.

This post is for the after.

Here's What's Actually Happening, By the Numbers

Real-world studies show 20% to 50% of people discontinue GLP-1 medications within the first year of starting them, far higher than the carefully managed populations in clinical trials (Thomsen et al., 2025).

• A 2025 nationwide Danish registry study following over 77,000 adults found 52% discontinued semaglutide within a year, with side effects and cost cited as leading drivers (Harrison, 2025).
  

• Across studies, side effects are the single most common reason people stop, accounting for roughly 28% of all discontinuations (Truveta, 2025).
  

• A January 2026 systematic review and meta-analysis in The BMJ, pulling together 37 studies and over 9,300 participants, found that after stopping any weight-management medication, people regain weight at an average rate of 0.4 kg per month, projected to return to starting weight within roughly 1.5 to 2 years (West et al., 2026).
  

• The STEP 1 trial extension, looking specifically at semaglutide, found that within one year of stopping, participants regained about two-thirds of the weight they'd lost (Wilding et al., 2022).
  

Read that last one again. Two-thirds. Not because people “gave up.” Because that's what the data shows happens to the average person who stops without something else in place underneath it.

This is not a story about your discipline. It's a story about what the medication was, and wasn't, ever built to do.

What GLP-1 Can Do. What It Can't.

GLP-1 medications work by mimicking a hormone your body already makes, one that slows digestion, increases satiety, and quiets what a lot of people call “food noise” (Garvey et al., 2022). That's real. For a lot of people, it's the first time in years food has gone quiet enough to think clearly.

Here's what it was never built to do: decide what you eat when it goes quiet. Build the habit of cooking at home. Teach you what a balanced plate looks like. Or make the decision for you on the Tuesday it wears off, runs out, or gets too expensive to refill.

We said this back in 2024, and the research since then has only confirmed it harder: you cannot medicate your way out of something you're eating yourself into. Medication treats a symptom. It was never the lifestyle.

The behavioral and dietary intervention underneath it was always going to be the foundation. The STEP trials say so themselves: behavioral intervention incorporating modifications in diet and physical activity remains the foundation of treatment for overweight and obesity (Garvey et al., 2022; Rubino et al., 2021; Wadden et al., 2021).

The Reframe We Want You to Sit With

The medication didn't quit on you. It just stopped covering for habits that were never built.

That's not a guilt trip, it's permission. The regain wasn't a verdict on your character. It was the predictable result of a tool doing its job (quieting appetite) while the decision, what to eat, how to move, how to handle a hard day without food as the answer, never got transferred back to you.

So if you started and stopped: the work in front of you isn't “get back on the medication” or “white-knuckle it alone.” It's build the infrastructure the medication was masking the absence of, starting today, regardless of whether you're on it, between doses, or off it for good.

What's Still Yours to Control

You can't change your genetics, your age, or your environment. Those are nonmodifiable. But two things remain entirely yours, medicated or not:

1. What you eat. Foods naturally high in fiber, lean protein, and healthy fats trigger your own GLP-1 release, think leafy greens, beans and lentils, oats, fish, eggs, Greek yogurt, avocado, chia and flax.
   

2. How you move. Daily physical activity, even in small doses, is one of the most consistent predictors of who keeps weight off long term.

   
   

These are the two sustaining factors no medication can produce or replace. They're also the two things we build with you every week, whether or not a GLP-1 is part of your plan

We Have Some Truth We Need You to Hear

We're not anti-medication. We've coached clients through starting GLP-1s, staying on them, and coming off them, and our job in every version of that story is the same: build the habits underneath whatever tool you're using.

If you started and stopped and you're standing in the regain right now feeling like you failed, you didn't. You're standing exactly where the research says most people stand. The questin is, what are you deciding, today, regardless of what's in the syringe?

Structure over struggle, always.

References

CDC. (2023). Adult obesity prevalence maps. Centers for Disease Control and Prevention. https://www.cdc.gov/obesity/data/prevalence-maps.html

Chinn, J. J., Martin, I. K., & Redmond, N. (2021). Health equity among Black women in the United States. Journal of Women's Health, 30(2), 212–219.

Garvey, W. T., Batterham, R. L., Bhatta, M., et al. (2022). Two-year effects of semaglutide in adults with overweight or obesity: The STEP 5 trial. Nature Medicine, 28(10), 2083–2091. https://doi.org/10.1038/s41591-022-02026-4

Harrison, C. (2025, September 15). Real-world study finds over 50% stop GLP-1s within 1 year. Medscape.

Office of Minority Health. (n.d.). Obesity and African Americans. U.S. Department of Health and Human Services. https://minorityhealth.hhs.gov/obesity-and-african-americans

Rubino, D., Abrahamsson, N., Davies, M., et al. (2021). Effect of continued weekly subcutaneous semaglutide vs placebo on weight loss maintenance in adults with overweight or obesity. JAMA, 325(14), 1414–1425. https://doi.org/10.1001/jama.2021.3224

Thomsen, R. W., Mailhac, A., Løhde, J. B., & Pottegård, A. (2025). Real-world evidence on the utilization, clinical and comparative effectiveness, and adverse effects of newer GLP-1RA-based weight-loss therapies. Diabetes, Obesity and Metabolism, 27(Suppl. 2), 66–88. https://doi.org/10.1111/dom.16364

Truveta. (2025). Real-world temporal and indication-specific variation in drivers of GLP-1 RA discontinuation [ISPOR 2025 poster summary].

Wadden, T. A., Bailey, T. S., Billings, L. K., et al. (2021). Effect of subcutaneous semaglutide vs placebo as an adjunct to intensive behavioral therapy on body weight in adults with overweight or obesity. JAMA, 325(14), 1403–1413. https://doi.org/10.1001/jama.2021.1831

West, S., Scragg, J., Aveyard, P., Oke, J. L., Willis, L., Haffner, S. J. P., Knight, H., Wang, D., Morrow, S., Heath, L., Jebb, S. A., & Koutoukidis, D. A. (2026). Weight regain following the cessation of medication for weight management: A systematic review and meta-analysis. BMJ. https://doi.org/10.1136/bmj-2025-085304

Wilding, J. P. H., Batterham, R. L., Davies, M., et al. (2022). Weight regain and cardiometabolic effects after withdrawal of semaglutide: The STEP 1 trial extension. Diabetes, Obesity and Metabolism, 24(8), 1553–1564. https://doi.org/10.1111/dom.14725